Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA ®  (pembrolizumab) in first line (1L) refractory/metastatic HPV+ Head and Neck Cancer patients Data to date from CUE-101 in combination with pembrolizumab demonstrates more than

BOSTON , Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business and

BOSTON , Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will

BOSTON , June 14, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will

BOSTON , June 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will

BOSTON , June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will

As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable stable disease (DSD) responses, two of which have tumor burden reductions of -18% and -24% and

Company to host Investor Update call on June 14, 2023   to review and discuss the clinical progress and associated data presented at ASCO BOSTON , May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable

BOSTON , May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business and financial

BOSTON , May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will take